Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD

Csoma, Balázs; Bikov, András; Nagy, Lajos; Tóth, Bence; Tábi, Tamás; Szűcs, Gergő; Komlósi, Zsolt István; Müller, Veronika; Losonczy, György; Lázár, Zsófia

doi:10.1186/s12931-019-1133-8

Cited by 43 publications

(31 citation statements)

References 46 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vulnerable populations in the current pandemic may have lower levels of endogenously produced NO. NO generated from eNOS drops off with age, and patients with chronic vascular inflammation, such as in type 2 diabetes, metabolic syndrome, chronic obstructive pulmonary disease, obesity, autoimmune disorders and hemoglobinopathies, may produce less eNOS [ 34 , 39 , 40 ]. Additionally, ACE activity relative to ACE2 activity may be elevated in patients with chronic vascular inflammation [ 41 , 42 ].…”

Section: The Rationale For Nitric Oxide Usementioning

confidence: 99%

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

et al. 2020

View full text Add to dashboard Cite

The ongoing outbreak of COVID-19 has quickly become a daunting challenge to global health. In the absence of targeted therapy and a reported 5.5% case fatality rate in the United States, treatments preventing rapid cardiopulmonary failure are urgently needed. Clinical features, pathology and homology to better understood pathogens suggest that uncontrolled inflammation and a cytokine storm likely drive COVID-19's unrelenting disease process. Interventions that are protective against acute lung injury and ARDS can play a critical role for patients and health systems during this pandemic. Nitric oxide is an antimicrobial and anti-inflammatory molecule with key roles in pulmonary vascular function in the context of viral infections and other pulmonary disease states. This article reviews the rationale for exogenous nitric oxide use for the pathogenesis of COVID-19 and highlights its potential for contributing to better clinical outcomes and alleviating the rapidly rising strain on healthcare capacity.

show abstract

Section: The Rationale For Nitric Oxide Usementioning

confidence: 99%

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The reasons why COPD patients with PVD show greater systemic vascular disease are not clear. Airway inflammation has been previously linked with reduced vascular nitric oxide production, 27 which could possibly explain a mechanism for endothelial dysfunction. However, the hypothesis of a "spillover" of inflammatory mediators from the lung to the systemic circulation is not supported by the current findings, since there were no consistent differences among groups in the inflammatory mediators that were tested.…”

Section: Discussionmentioning

confidence: 99%

<p>Association Between Systemic and Pulmonary Vascular Dysfunction in COPD</p>

Piccari¹,

Pozo²,

Blanco³

et al. 2020

COPD

View full text Add to dashboard Cite

Introduction: In chronic obstructive pulmonary disease (COPD), endothelial dysfunction and stiffness of systemic arteries may contribute to increased cardiovascular risk. Pulmonary vascular disease (PVD) is frequent in COPD. The association between PVD and systemic vascular dysfunction has not been thoroughly evaluated in COPD. Methods: A total of 108 subjects were allocated into four groups (non-smoking controls, smoking controls, COPD without PVD and COPD with PVD). In systemic arteries, endothelial dysfunction was assessed by flow-mediated dilation (FMD) and arterial stiffness by pulse wave analysis (PWA) and pulse wave velocity (PWV). PVD was defined by a mean pulmonary artery pressure (PAP) ≥25 mmHg at right heart catheterization or by a tricuspid regurgitation velocity >2.8 m/s at doppler echocardiography. Biomarkers of inflammation and endothelial damage were assessed in peripheral blood. Results: FMD was lower in COPD patients, with or without PVD, compared to nonsmoking controls; and in patients with COPD and PVD compared to smoking controls. PWV was higher in COPD with PVD patients compared to both non-smoking and smoking controls in a model adjusted by age and the Framingham score; PWV was also higher in patients with COPD and PVD compared to COPD without PVD patients in the non-adjusted analysis. FMD and PWV correlated significantly with forced expiratory volume in the first second (FEV 1), diffusing capacity for carbon monoxide (DL CO) and systolic PAP. FMD and PWV were correlated in all subjects. Discussion: We conclude that endothelial dysfunction of systemic arteries is common in COPD, irrespective if they have PVD or not. COPD patients with PVD show increased stiffness and greater impairment of endothelial function in systemic arteries. These findings suggest the association of vascular impairment in both pulmonary and systemic territories in a subset of COPD patients.

show abstract

“…These molecules play important role in the leukocyte adhesion and in the rolling to the focus of the inflammatory process although others factors are important to the leukocyte migration phenomenon. NO is an important mediator in the leukocyte migration, promoting vasodilation and reducing the recruitment, adhesion, rolling, and leukocyte migration during inflammatory response favoring diapedesis [ 40 , 41 ]. Since EEGC did not increase the NO levels induced by zymosan, it led us to conclude that the EEGC mechanism of action was not involved in the NO pathway.…”

Section: Discussionmentioning

confidence: 99%

Antiarthritic and Antihyperalgesic Properties of Ethanolic Extract fromGomphrena celosioidesMart. (Amaranthaceae) Aerial Parts

Macorini

Radai

Maris

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Gomphrena celosioides Mart. (Amaranthaceae) is used in folk medicine as a natural analgesic, and in Brazil, the species of genus Gomphrena is used for rheumatism. However, scientific evidence which supports its popular use as an analgesic is scarce. This study assessed the antiarthritic and antihyperalgesic activities of the ethanolic extract obtained from G. celosioides aerial parts on Swiss or C57BL/6 mice. The antiarthritic and antihyperalgesic potential of Gomphrena celosioides was evaluated using paw edema, mechanical hyperalgesia, cold allodynia, carrageenan-induced pleurisy, articular inflammation zymosan-induced, Freund’s complete adjuvant-induced inflammation zymosan-induced peritonitis, and carrageenan-induced adhesion and rolling experiment models. All doses of G. celosioides (300, 700, and 1000 mg/kg) significantly reduced edema formation in all the intervals evaluated, whereas the mechanical hyperalgesia was reduced 3 hours after the carrageenan injection. The cold hyperalgesia was significantly decreased 3 (700 mg/kg) and 4 hours (700 and 1000 mg/kg) after the carrageenan injection. Ethanolic extract of G. celosioides at 1000 mg/kg reduced the total leukocyte number, without interfering in the protein extravasation in carrageenan-induced pleurisy model. Ethanolic extract of G. celosioides (300 mg/kg) was also able to reduce significantly the leukocyte migration in zymosan-induced articular edema, while a reduction of the adhesion and migration and leukocyte rolling was induced by the ethanolic extract of G. celosioides (300 mg/kg) in zymosan-induced peritonitis. In Freund’s complete adjuvant-induced inflammation model, an edema formation and mechanical hyperalgesia reduction were induced by the ethanolic extract of G. celosioides on day 22, whereas the cold allodynia was reduced on day 6 of treatment with the extract. These results show that ethanolic extract of G. celosioides has antihyperalgesic and antiarthritic potential in different acute and persistent models, explaining, at least in part, the ethnopharmacological relevance of this plant as a natural analgesic agent.

show abstract

Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD

Cited by 43 publications

References 46 publications

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

<p>Association Between Systemic and Pulmonary Vascular Dysfunction in COPD</p>

Antiarthritic and Antihyperalgesic Properties of Ethanolic Extract fromGomphrena celosioidesMart. (Amaranthaceae) Aerial Parts

Contact Info

Product

Resources

About